Table.

Characteristics of Included Studies

Sourcea	Study Design	Length of Follow- up, mo	Sample Sizeb	Age, mean, y	Outcome Measure
Baumann and Blumenstock,12 2005 (Germany)	CS (prospective), consecutive patients	3	121	47.9	BP (SF-36)
Brandsted and Sindwani,13 2007 (USA)	Record review (retrospective), consecutive patients	12	40	45	BP (SF-8)c
Davis et al,20 2005 (USA)	CS (prospective), consecutive patients	12	51	45.9	BP (SF-36)
Durr and Desrosiers,14 2003 (Canada)	CS (prospective), consecutive patients	3	47	43.7	BP (SF-36)
Gliklich and Hilinski,15 1995 (USA)	CS (prospective), consecutive patients	3	40	42.6	BP (SF-36)
Gliklich and Metson,16 1997 (USA)	CT (prospective), consecutive patients	6	108	42.7	BP (SF-36)
Hosemann et al,17 2003 (Germany)	CS (prospective), consecutive patients	6	103	44	BP (SF-36)
Khalid et al,18 2004 (USA)	Retrospective, randomly selected patients	36	150	46.9	BP (SF-36)
Ragab et al,21 2004 (United Kingdom)	RCT (prospective), consecutive patients	12	40	43	BP (SF-36)
Winstead and Barnett,19 1998 (USA)	CS (prospective), consecutive patients	12	43	34	BP (SF-36)
Zuo et al,6 2007 (China)	CS (prospective), randomly selected patients	6	115	33.5	BP (SF-36)

Abbreviations: BP, bodily pain; CS, cohort study; CT, clinical trial; RCT, randomized controlled trial; SF-8, 8-Item Short Form Health Survey; SF-36, 36-Item Short Form Health Survey.

^aAdditional information was obtained about the following studies: Baumann and Blumenstock¹² (from I. Baumann, MD, e-mail communication, May 2007); Davis et al²⁰ (from G. E. Davis, MD, MPH, e-mail communication, May, 2008); Hosemann et al¹⁷ (from W. Hosemann, MD, e-mail communication, June 2007); and Ragab et al²¹ (from V. J. Lund, MS, FRCS, FRCS(Edin), written correspondence, December 2004).

^bNumber of patients with final outcome data.

^cFor the purposes of this study, results from the SF-8 are considered with those from the SF-36.